Merck reported strong revenue and earnings growth, raised its full-year guidance, and showcased robust performance across key product lines like KEYTRUDA and GARDASIL. Management's optimistic outlook and strategic investments in the pipeline indicate confidence in continued short-term gains. These positive indicators are likely to boost investor sentiment in the near term.

[2]